Please wait while the formulary information is being retrieved.
Drug overview for DAPSONE (dapsone):
Generic name: DAPSONE (DAP-sone)
Drug class: Antiprotozoal Agents
Therapeutic class: Anti-Infective Agents
Dapsone, a synthetic sulfone, is an antimycobacterial and antiprotozoal agent.
No enhanced Uses information available for this drug.
Generic name: DAPSONE (DAP-sone)
Drug class: Antiprotozoal Agents
Therapeutic class: Anti-Infective Agents
Dapsone, a synthetic sulfone, is an antimycobacterial and antiprotozoal agent.
No enhanced Uses information available for this drug.
DRUG IMAGES
DAPSONE 100 MG TABLET
DAPSONE 25 MG TABLET
The following indications for DAPSONE (dapsone) have been approved by the FDA:
Indications:
Dermatitis herpetiformis
Leprosy
Professional Synonyms:
Bullous dermatitis herpetiformis
Hansen's disease
Indications:
Dermatitis herpetiformis
Leprosy
Professional Synonyms:
Bullous dermatitis herpetiformis
Hansen's disease
The following dosing information is available for DAPSONE (dapsone):
No enhanced Dosing information available for this drug.
Dapsone is administered orally. For administration to children, commercially available tablets of dapsone have been crushed and dissolved in strawberry syrup; however, studies evaluating bioavailability of the drug following administration of this preparation have not been published to date.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| DAPSONE 100 MG TABLET | Maintenance | Adults take 1 tablet (100 mg) by oral route once daily |
| DAPSONE 25 MG TABLET | Maintenance | Adults take 1 tablet (25 mg) by oral route once daily |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| DAPSONE 25 MG TABLET | Maintenance | Adults take 1 tablet (25 mg) by oral route once daily |
| DAPSONE 100 MG TABLET | Maintenance | Adults take 1 tablet (100 mg) by oral route once daily |
The following drug interaction information is available for DAPSONE (dapsone):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Dapsone/Rifamycins SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The exact mechanism is unknown but likely involves induction of hepatic enzymes resulting in increased clearance of dapsone.(1-3) CLINICAL EFFECTS: Concurrent use may lead to decreased levels and clinical effects of dapsone when it is used for treatment or prophylaxis of Pneumocystis jiroveci pneumonia (PCP).(1-5) Since dapsone is extremely potent for treatment of leprosy, this interaction is not clinically relevant in the setting of leprosy.(5) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US Department of Health and Human Service guidelines for prevention and treatment of opportunistic infections in patients with HIV recommend avoiding concomitant administration of dapsone with rifamycins if possible and considering use of alternatives to dapsone.(4) Since dapsone is extremely potent for treatment of leprosy, this interaction is not clinically relevant in the setting of leprosy.(5) DISCUSSION: When given with rifampin, dapsone levels have been found to decrease by 7- to 10-fold.(3,4) In a trial of 16 HIV-positive patients, rifabutin (300 mg daily) lowered the area-under-curve (AUC) of dapsone (50 mg daily) by 27% to 40%.(2,4) Although dapsone dose adjustment is not necessary when it is used for leprosy, the implications of this interaction when dapsone is used for PCP is unknown. Mycobacterium leprae is very sensitive to dapsone, with a minimum inhibitory concentration (MIC) of 2.5 to 10 mcg/L. In contrast, the MIC of dapsone against P. jiroveci is 100 to 10,000 mcg/L. Dapsone concentrations reached with typical PCP therapy is in the range of 100 to 7,000 mcg/L. Thus, a 10-fold reduction in dapsone levels could result in dapsone levels below the MIC for PCP.(5) |
PRIFTIN, RIFABUTIN, RIFADIN, RIFAMPIN, TALICIA |
There are 0 moderate interactions.
The following contraindication information is available for DAPSONE (dapsone):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 3 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Glucose-6-phosphate dehydrogenase (g6Pd) deficiency |
| Hemoglobin H disease |
| Hemolytic anemia from pyruvate kinase and g6PD deficiencies |
There are 2 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Anemia |
| NADH methemoglobin reductase deficiency |
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Disease of liver |
The following adverse reaction information is available for DAPSONE (dapsone):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 19 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Allergic dermatitis Hemolytic anemia Methemoglobinemia Skin rash Urticaria |
None. |
| Rare/Very Rare |
|---|
|
Agranulocytosis Altered mental status Anemia Blood dyscrasias Exfoliative dermatitis Fever Glucose-6-phosphate dehydrogenase (g6Pd) deficiency anemia Hepatocellular damage Jaundice Lymphadenopathy Malaise Mood changes Peripheral neuropathy Pruritus of skin |
There are 7 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Anorexia Gastrointestinal irritation Headache disorder Insomnia Nausea Nervousness Vomiting |
The following precautions are available for DAPSONE (dapsone):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Animal reproduction studies have not been performed with dapsone. Although dapsone has been used in pregnant women without evidence of fetal abnormalities, the drug should be used during pregnancy only when clearly needed. In patients with leprosy, some clinicians recommend maintaining dapsone treatment during pregnancy. In addition, dapsone has been important for the management of dermatitis herpetiformis in some pregnant women.
Because dapsone is distributed into milk and because of the tumorigenic potential demonstrated in animal studies, a decision should be made to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for DAPSONE (dapsone):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for DAPSONE (dapsone)'s list of indications:
| Dermatitis herpetiformis | |
| L12.2 | Chronic bullous disease of childhood |
| L13.0 | Dermatitis herpetiformis |
| Leprosy | |
| A30 | Leprosy [hansen's disease] |
| A30.0 | Indeterminate leprosy |
| A30.1 | Tuberculoid leprosy |
| A30.2 | Borderline tuberculoid leprosy |
| A30.3 | Borderline leprosy |
| A30.4 | Borderline lepromatous leprosy |
| A30.5 | Lepromatous leprosy |
| A30.8 | Other forms of leprosy |
| A30.9 | Leprosy, unspecified |
Formulary Reference Tool